Apr 27, 2022
Starpharma to present DEP® at Boston ADC summit (ASX Announcement)
Melbourne, Australia; 27 April 2022: Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that it will today present as an invited speaker at the Novel Format Conjugates Summit, an industry conference focusing on next generation Non-Traditional Antibody Drug Conjugates (ADCs) for oncology and beyond.
There is an increasing interest in novel approaches to the development of ADCs. The conference, organised by World ADC, brings together international thought leaders to share cutting-edge scientific advances from the world of alternative format conjugates. The industry event is taking place in Boston on 25-27 April 2022 and involves speakers and attendees from international companies, including AstraZeneca, Merck, Lilly, Sanofi, Takeda, Regeneron, Debiopharm, Bicycle Therapeutics, and Avidity.
Starpharma will present the company’s DEP® platform, with a particular focus on the use of DEP® in ADCs and radiotheranostics. Starpharma’s presentation ‘Targeted DEP® Drug Delivery’ includes:
- Overview of dendrimer enhanced products (DEP®), including Starpharma’s targeted DEP® ADCs and DEP® radiotheranostics programs
- Benefits of DEP® in ADCs, including achieving high drug antibody ratio, enhanced PK/Biodistribution and efficacy outcomes, flexibility in targeting moiety and payload
- Benefits of DEP® in radiotheranostics, including superior tumour targeting and better efficacy outcomes, flexibility in targeting moiety and radioisotope of therapeutic or diagnostic applications
Starpharma will also be conducting partnering discussions with other pharmaceutical companies attending the conference.
An abridged copy of the presentation can be downloaded here: Novel Format Conjugate Summit 25-27 April 2022 (pdf file, 1975kb)
Download full announcement here: Starpharma to present DEP® at Boston ADC summit (PDF 225KB)
This contains certain forward-looking statements.